APA

Guo C., Fulp J. W., Jiang Y., Li X., Chojnacki J. E., Wu J., Wang X. & Zhang S. (20180710). Development and Characterization of a Hydroxyl-Sulfonamide Analogue, 5-Chloro-N-[2-(4-hydroxysulfamoyl-phenyl)-ethyl]-2-methoxy-benzamide, as a Novel NLRP3 Inflammasome Inhibitor for Potential Treatment of Multiple Sclerosis. : ACS chemical neuroscience.

Chicago

Guo Chunqing, Fulp Jacob W, Jiang Yuqi, Li Xia, Chojnacki Jeremy E, Wu Jingde, Wang Xiang-Yang and Zhang Shijun. 20180710. Development and Characterization of a Hydroxyl-Sulfonamide Analogue, 5-Chloro-N-[2-(4-hydroxysulfamoyl-phenyl)-ethyl]-2-methoxy-benzamide, as a Novel NLRP3 Inflammasome Inhibitor for Potential Treatment of Multiple Sclerosis. : ACS chemical neuroscience.

Harvard

Guo C., Fulp J. W., Jiang Y., Li X., Chojnacki J. E., Wu J., Wang X. and Zhang S. (20180710). Development and Characterization of a Hydroxyl-Sulfonamide Analogue, 5-Chloro-N-[2-(4-hydroxysulfamoyl-phenyl)-ethyl]-2-methoxy-benzamide, as a Novel NLRP3 Inflammasome Inhibitor for Potential Treatment of Multiple Sclerosis. : ACS chemical neuroscience.

MLA

Guo Chunqing, Fulp Jacob W, Jiang Yuqi, Li Xia, Chojnacki Jeremy E, Wu Jingde, Wang Xiang-Yang and Zhang Shijun. Development and Characterization of a Hydroxyl-Sulfonamide Analogue, 5-Chloro-N-[2-(4-hydroxysulfamoyl-phenyl)-ethyl]-2-methoxy-benzamide, as a Novel NLRP3 Inflammasome Inhibitor for Potential Treatment of Multiple Sclerosis. : ACS chemical neuroscience. 20180710.